TerminatedPhase 3NCT02999854
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
Studying Inherited acute myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kiadis Pharma
- Principal Investigator
- Denis Claude Roy, Prof MDResearch Center and Cellular Therapy Laboratory, Maisonneuve-Rosemont Hospital (Montreal, Canada)
- Intervention
- ATIR101(biological)
- Enrollment
- 63 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2017 – 2021
Study locations (30)
- City of Hope National Medical Center, Duarte, California, United States
- Moores UC San Diego Cancer Center, La Jolla, California, United States
- UCLA Center for Health Sciences, Los Angeles, California, United States
- Stanford University School of Medicine, Stanford, California, United States
- Emory University, Atlanta, Georgia, United States
- University of Kansas Cancer Center, Westwood, Kansas, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Weill Cornell Medical College, New York, New York, United States
- Columbia University Medical Center, New York, New York, United States
- Stony Brook University Hospital, Stony Brook, New York, United States
- Oregon Health & Science University, Portland, Oregon, United States
- Universitair Ziekenhuis Antwerpen, Antwerp, Belgium
- Algemeen Ziekenhuis Sint-Jan, Bruges, Belgium
- Institut Jules Bordet, Brussels, Belgium
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02999854 on ClinicalTrials.govOther trials for Inherited acute myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT04460950Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid NeoplasmsGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGNCT03058588Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic SyndromesAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia